|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Thoracic Oncology Section (Drs. Finkelstein, Schrump, and Nguyen, and Ms. Kunst), Surgery Branch, Center for Cancer Research, the National Cancer Institute, the Laboratory of Pathology (Dr. Hewitt), and the Diagnostic Radiology Department (Dr. Summers), National Institutes of Health, Bethesda, MD.
Correspondence to: Ronald M. Summers, MD, PhD, National Institutes of Health, Building 10, Room 1C660, 10 Center Dr, MSC 1182, Bethesda, MD 20892-1182; e-mail: rms{at}nih.gov
| Abstract |
|---|
|
|
|---|
Design: Prospective observer study, in which 44 consecutive patients with thoracic malignancies were evaluated using several diagnostic imaging modalities. Images of the thorax were interpreted by individuals blind to the results of FB for the detection of endoluminal, obstructive, or mucosal lesions.
Measurements and results: Image acquisition and simulation of the tracheobronchial anatomy were created successfully in all patients. Thirty-two patients who underwent both SHR-CT scanning and VB had correlative FBs within 1 month. In all nine patients who had a normal anatomy, SHR-CT scanning and VB accurately correlated with the FB findings. However, CT scanning demonstrated two false-positive obstructive lesions in one patient. Twenty-three patients had a total of 35 abnormal FB findings. The sensitivities of SHR-CT scanning and VB for the detection of endoluminal, obstructive, and mucosal lesions were 90%, 100%, and 16%, respectively. The overall sensitivities and specificities of SHR-CT scanning and VB were 83% and 100%, respectively. In contrast, CT scanning had sensitivities of 50%, 72%, and 0% for the detection of endoluminal, obstructive, and mucosal lesions with an overall sensitivity and specificity of 59%, and 85%, respectively. There was no case in which conventional CT scanning was better at detecting lesions than either SHR-CT scanning or VB.
Conclusions: SHR-CT scanning and VB are accurate, noninvasive methods for identifying obstructions and endoluminal lesions within the respiratory tract. Thus, these novel imaging techniques are valuable as complementary modalities to FB, providing information that is useful for the detection and management of airway malignancies.
Key Words: bronchoscopy cancer CT endoscopy imaging thoracic virtual
| Introduction |
|---|
|
|
|---|
Patients with suspected tracheobronchial lesions typically undergo diagnostic evaluation consisting of conventional CT scanning and fiberoptic bronchoscopy (FB).3 Conventional two-dimensional cross-sectional CT images of the chest have a reported sensitivity and specificity of 60 to 100% for the detection of obstructive lesions in the respiratory tract.4 5 6 The limitations of the accuracy of conventional CT scans include suboptimal scanning techniques, inappropriately thick slices, and artifacts between sections.7 Currently, FB remains the best modality for the evaluation of endoluminal and mucosal lesions in the respiratory tract. However, this imaging modality frequently provides little information concerning the extent of extraluminal disease or airway patency distal to high-grade bronchial stenoses.8
Novel imaging modalities, such as super high-resolution CT (SHR-CT) scanning and virtual bronchoscopy (VB), are currently available for the noninvasive evaluation of tracheobronchial neoplasms. SHR-CT scanning involves the acquisition of several hundred images of the chest using a multislice helical CT scanner. Indeed, conventional CT scans may acquire only 20 to 50 images of the entire chest. High-resolution CT scans may image 50 contiguous cuts through a specific area of concern within the thorax. SHR-CT scans acquire 200 to 300 contiguous 1.25-mm cross-sections of the entire thorax. The radiation dose associated with SHR-CT scans is the same or slightly less than that of a conventional CT scan.
VB (also known as CT bronchography) employs three-dimensional (3-D) reconstruction of high-resolution helical CT images of the tracheobronchial tree.9 The contrast between the airway lumen and wall enables the generation of a 3-D anatomic model of tracheobronchial anatomy that provides views similar to those obtained during FB.6 Furthermore, VB enables the visualization of the tracheobronchial anatomy from multiple angles, thereby facilitating the analysis of bronchial lesions beyond the limits of FB and the assessment of airway patency distal to high-grade obstructions.8
Currently, limited information is available regarding the utility of SHR-CT scanning and VB relative to conventional diagnostic modalities of tracheobronchial lesions in oncology patients. Following an initial preliminary study to determine the feasibility of VB, the current study was undertaken to evaluate directly the diagnostic potential of conventional CT, SHR-CT scanning, and VB scans relative to FB for the detection of tracheobronchial lesions. Thus, this study explores the utility of SHR-CT scanning and VB to evaluate the tracheobronchial anatomy with respect to the diagnosis and selection of patients for resection, dilation, and laser, or photodynamic ablation of high-grade stenoses, as well as enabling the sequential evaluation of treatment response in patients with tracheobronchial neoplasms. Indeed, a practical algorithm employing noninvasive techniques for patients who are at high risk for airway pathology may have important clinical benefits.
| Materials and Methods |
|---|
|
|
|---|
The mean (± SD) age of all patients was 52 ± 12.2 years (median, 53 years; range, 29 to 88 years). Thirty-two patients (73%) were men (mean age, 52 ± 11.3 years; median age, 54 years; age range, 29 to 73 years), 12 patients (27%) were women (mean age, 52 ± 14.8 years; median age, 51 years; age range, 38 to 88 years). Histologic diagnoses included non-small cell lung cancer (16 patients), small cell lung cancer (3 patients), metastatic renal cell cancer (12 patients), metastatic melanoma (7 patients), metastatic thyroid cancer (2 patients), sarcoma (1 patient), carcinoid (1 patient), teratoma (1 patient), and esophageal cancer (1 patient).
Procedures
For each FB, visualization and interpretation of the tracheobronchial tree were achieved under the direction of the attending thoracic surgeons (DSS and DMN) who were blinded to the radiologists interpretation of the imaging modalities. FB findings, which were entered into the database, included the presence or absence of obstructive lesions (ie, a bronchial narrowing of > 50%), endoluminal masses (ie, a mass protruding into the lumen with < 50% occlusion), or mucosal lesions (ie, hemorrhage, erythema, or tissue friability).
For each conventional CT scan, 20 to 50 images of the thorax were obtained, according to the standard of care. The technique was 510 collimation, HQ mode (ie, helical pitch, 1 to 3, 11.25 mm table motion per rotation, 120 kVp, 280 mA, 0.8 s tube rotation) and nonoverlapping reconstructions with a section interval of 5 to 10 mm in one held breath using a multislice helical CT scanner.
For each SHR-CT scan, 200 to 300 contiguous 1.25-mm images of the thorax were obtained in one or two 17-s breathhold maneuvers (LightSpeed QX/I multislice helical CT scanner; General Electric; Milwaukee, WI).10 The technique was 1.25 collimation, HS mode (helical pitch, 6, 7.5 mm table motion per rotation, 120 kVp, 100 mA, and 0.8 s tube rotation), nonoverlapping reconstructions with a section interval of 1.25 mm, and an effective z-axis resolution of approximately 1.6 mm. The manufacturers "standard" reconstruction algorithm was used. The multiple scan average dose to the scanned volume was 1.58 rad at the surface and 0.78 rad in the center per examination. The calculated radiation dose with this technique was the same or slightly less than that of a conventional thoracic CT scan.9
VB images were converted to 3-D endoscopic views using commercial software (Navigator; General Electric) on a workstation (Advantage Windows; General Electric). The VB was derived from the SHR-CT axial images of the thorax with no further radiation exposure necessary. The radiologist (RMS), who was blinded to the findings of the other modalities, first placed the viewpoint in the proximal trachea. Retrograde inspection of the subglottic area of the trachea was performed. Subsequent analysis consisted of sequential antegrade inspection of the trachea, mainstem bronchi, lobar bronchi, and segmental bronchi. Little additional time was needed to perform and interpret the images. For the purpose of this study, the interpretation of the VB reconstruction was kept to < 10 min for all cases.
All detected abnormalities in the tracheobronchial tree were recorded in the database. All SHR-CT and VB scans and FBs were interpreted in a blinded manner. The presence or absence of obstructive lesions (ie, bronchial narrowing of > 50%), endoluminal masses (ie, a mass protruding into the lumen with < 50% occlusion), or mucosal lesions (ie, hemorrhage, erythema, or tissue friability) were recorded. In addition, the anatomic locations of the detected lesions were noted.
Statistical Analysis
The results of the imaging modalities were compared directly with actual FB findings at the same anatomic sites. A true-positive (TP) result occurred when the finding of the imaging modality equaled that of FB, when FB visualized a lesion. A true-negative (TN) result occurred when the finding of the imaging modality equaled that of FB, when the FB finding was within normal limits. A false-negative (FN) result occurred when an imaging modality failed to detect a lesion that had been documented during FB. A false-positive (FP) result occurred when an imaging modality demonstrated an abnormality but FB had revealed the area to be normal. The overall sensitivity (ie, TP/[TP + FN]) and specificity (ie, TN/[TN + FP]) of each imaging modality was determined. A subanalysis was performed for obstructive lesions, endoluminal masses, and mucosal lesions.
| Results |
|---|
|
|
|---|
SHR-CT and VB
Of the 32 patients who underwent correlative FBs, 9 (28%) had normal examination findings. In all patients with normal anatomy, the results of SHR-CT scans and VB accurately correlated with those of FBs (Web movie 1; available online at http://www.chestjournal.org/cgi/content/full/124/5/1834/DC1).
In the remaining 23 patients, a total of 35 abnormal FB findings were detected (Figs 1 and 2 ). With respect to the location of FB findings, there were 20 lesions (57%) in the right lung, 12 lesions (34%) in the left lung, and 3 lesions (9%) in the trachea/carina. There appeared to be some clustering of lesions (13 of 35 lesions [37%]) at the right mainstem and right upper lobe. Of these 13 lesions, 9 were obstructive, 2 were endoluminal, and 2 were mucosal. Lesions beyond the proximal segmental bronchi were difficult to visualize by FB due to the size of the endoscope (Fig 3 ).
|
|
|
|
On the other hand, SHR-CT scans revealed 10 additional lesions, and VB demonstrated 11 additional lesions that were not evaluable by FB (Fig 3 , bottom left, D, and bottom middle, E) due to the size limitation of the bronchoscope (9 cases) or to the location distal to high-grade stenoses (2 cases). Because many patients went on to undergo resection of a lesion for palliation or cure, pathologic correlation was attainable in nine cases. Of these nine cases, six obstructive lesions (67%) that had not been detected by FB but were visualized by SHR-CT scans and VBs were confirmed to be positive by pathology. With respect to the location of these pathology-proven distal lesions, two were located in the right lower lobe, two were located in the left lower lobe, one was located in the right middle lobe, and one was located in the left upper lobe (Fig 3 , bottom left, D, and bottom middle, E).
Conventional CT Scanning
Of the 32 patients who underwent correlative FBs, 25 (78%) obtained conventional CT scans in addition to SHR-CT scan and VBs. Seven patients (28%) had normal examination findings by FB. The results of conventional CT scans correlated with those of FBs in six of these patients (specificity, 85%). Conventional CT scans demonstrated two FP obstructive lesions in one patient (Table 1) .
Eighteen patients (72%) had a total of 29 abnormal FB findings. Conventional CT scans detected only 17 of these 29 abnormalities, including 13 of 18 obstructive lesions, 4 of 8 endoluminal masses, and 0 of 3 mucosal lesions. In contrast to SHR-CT scans and VBs, the sensitivity of conventional CT scanning was 72% for obstructive lesions, 50% for endoluminal masses, 0% for mucosal lesions, and 59% overall (Table 1) . Of the 12 FN lesions identified by FB and not detected by conventional CT scanning, only 3 abnormalities were not visualized by SHR-CT scanning and VB. This was due to the fact that conventional CT scanning was not obtained in those patients, and not because conventional CT scans could visualize the lesions missed by SHR-CT scans and/or VBs. Indeed, there was no case in which conventional CT scanning improved on the findings of either SHR-CT scans or VBs (Fig 3) .
As with SHR-CT scans and VBs, additional obstructive lesions were appreciated by CT scans that were not visualized by FB. Three of six of these obstructive lesions (50%) were confirmed to be positive by histologic evaluation. The locations of these lesions were in the left lower lobe (two lesions) and the right lower lobe (one lesion) [Fig 3 , bottom right, F].
| Discussion |
|---|
|
|
|---|
Preliminary studies reported by Finkelstein et al,9 Fleiter et al,12 Liewald et al,13 Rapp-Bernhardt and colleagues,14 15 and Seemann et al16 have demonstrated the feasibility and utility of VB in patients with primary or metastatic cancers involving the lungs and mediastinum (Table 2 ). However, limited information is available comparing SHR-CT scanning to other imaging modalities in this clinical context. Our current study was performed to directly compare in a prospective manner the diagnostic potentials of standard CT scanning, SHR-CT scanning, and VB relative to FB for the detection of tracheobronchial neoplasms. We observed that SHR-CT scanning and VB are excellent imaging modalities with sensitivities of 100% for the detection of obstructive stenotic lesions. Furthermore, these modalities are highly effective for assessing airway patency distal to high-grade stenoses and for identifying lesions in subsegmental bronchi. Therefore, SHR-CT scanning and VB had overall sensitivities of 83% for the detection of any abnormality in the tracheobronchial tree. However, these techniques are presently not effective for the detection of subtle mucosal abnormalities such as erythema or early sessile lesions. SHR-CT scans and VB may not be appropriate for identifying premalignant lesions in the respiratory tract. Nevertheless, technologies such as fiberoptic confocal microscopy, optical CT scanning, high-resolution ultrasonography, and positron emission tomography may complement the detection of these lesions in the near future.11
|
Our data indicate that SHR-CT scanning and VB are powerful, objective, and reproducible imaging modalities that can complement FB for the evaluation of tracheobronchial malignancies. As such, we propose the following algorithm for patients who are at high risk for airway pathology (Fig 4 ). Asymptomatic patients should undergo screening using conventional chest CT scans. Symptomatic individuals should undergo SHR-CT scans. If abnormalities are detected, VB can be used to further define and simulate airway anatomy before FB or surgery. This algorithm may limit the number of unnecessary SHR-CT scans and 3-D VB reconstructions while optimizing the decisions regarding appropriate therapeutic interventions with curative or palliative intent. Follow-up SHR-CT scans and VB would enable the serial evaluation of the treatment response in these individuals.
|
| Acknowledgements |
|---|
| Footnotes |
|---|
Dr. Summers has patents pending or has been awarded patents in the subject area of this article.
This research was supported by a Cancer Research Foundation of America, Young Investigator Travel Grant Award, and by the intramural research programs of the Diagnostic Radiology Department, National Institutes of Health, Bethesda, MD, and was a recipient of the Cecile Lehman Research Finalist Award at Chest 2002.
Presented in part at Chest 2002, San Diego, CA, November 5, 2002.
Supplemental movie materials are available online at http://www.chestjournal.org/cgi/content/full/124/5/1834/DC1.
Received for publication February 10, 2003. Accepted for publication May 19, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Hu and R. A. Malthaner The feasibility of three-dimensional displays of the thorax for preoperative planning in the surgical treatment of lung cancer Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 506 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Asahina, K. Yamazaki, Y. Onodera, E. Kikuchi, N. Shinagawa, F. Asano, and M. Nishimura Transbronchial Biopsy Using Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation Chest, September 1, 2005; 128(3): 1761 - 1765. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Jones and T. Athanasiou Is Virtual Bronchoscopy an Efficient Diagnostic Tool for the Thoracic Surgeon? Ann. Thorac. Surg., January 1, 2005; 79(1): 365 - 374. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |